Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: J Hepatol. 2018 Oct 1;70(1):108–117. doi: 10.1016/j.jhep.2018.09.023

Fig. 2. Exogenous inhibition of β-catenin using DsiRNA results in decreased injury after DDC.

Fig. 2.

(A) Treatment regimen for administration of DsiRNAs after DDC. (B) Western blot confirms decreased β-catenin protein after DsiRNA treatment; **p <0.01 vs. control+DDC (t test). (C) Gross liver specimens demonstrate that control livers become enlarged and dark red, while β-catenin DsiRNA-treated livers are smaller and lighter colored. LW/BW ratios are lower in β-catenin DsiRNA+DDC mice; *p <0.05 and **p <0.01 vs. treatment-matched controls (t test). (D) Both biliary and hepatic injury are decreased after β-catenin DsiRNA +DDC; **p <0.01 and ****p <0.0001 vs. control+DDC (t test). (E) Sirius red staining shows a reduction in fibrosis after β-catenin DsiRNA+DDC compared to control +DDC (50x). Quantification of representative Sirius red images demonstrates significantly less fibrosis in β-catenin DsiRNA+DDC; ***p <0.001 vs. control+DDC (t test). ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine; DsiRNA, dicer-substrate RNA; LW/BW, liver weight/body weight.